Short Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Declines By 14.0%

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a significant drop in short interest in March. As of March 13th, there was short interest totaling 12,316 shares, a drop of 14.0% from the February 26th total of 14,323 shares. Based on an average daily volume of 86,687 shares, the short-interest ratio is currently 0.1 days. Approximately 0.2% of the company’s stock are short sold.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in Neuphoria Therapeutics by 33.3% in the fourth quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock worth $67,000 after acquiring an additional 4,325 shares in the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Neuphoria Therapeutics during the third quarter valued at about $58,000. Commonwealth Equity Services LLC purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter valued at approximately $43,000. XTX Topco Ltd acquired a new stake in Neuphoria Therapeutics in the 4th quarter worth approximately $47,000. Finally, Boothbay Fund Management LLC acquired a new stake in Neuphoria Therapeutics in the 4th quarter worth approximately $54,000. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on NEUP shares. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. HC Wainwright cut their price target on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, December 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Neuphoria Therapeutics presently has an average rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Stock Performance

NASDAQ:NEUP traded up $0.39 during midday trading on Wednesday, reaching $4.46. 26,582 shares of the stock traded hands, compared to its average volume of 48,189. The stock has a market capitalization of $24.03 million, a PE ratio of -1.01 and a beta of 0.50. Neuphoria Therapeutics has a 12-month low of $3.64 and a 12-month high of $21.40. The business has a 50-day moving average of $4.27 and a two-hundred day moving average of $6.11.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.21). Research analysts anticipate that Neuphoria Therapeutics will post -1.56 earnings per share for the current year.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.